Logo Image
News
All NewsDosing & Delivery InnovationsPress ReleasesProduct Approvals and Launches
Video
All Video TypesAJMC TVGuidelinesInsightsOnLocationPayer PerspectivesPeer ExchangePost Conference PerspectivesShortsStakeholder Summit
Podcasts
Journals
All JournalsThe American Journal of Managed CarePopulation Health, Equity & OutcomesEvidence-Based OncologyAbout Supplements and Featured PublicationsSupplements and Featured Publications IssuesSubmit a Manuscript
More
Conferences
Conference CoverageConference ListingPost Conference Perspectives
Events
AJMC EventsEvents CalendarInstitute for Value-Based MedicinePatient-Centered Oncology CarePopulation Health RoundtablesWebinars
Resources
Interactive ToolsFormulary CentralClinical SpotlightMicrositesSponsored Content
CE
About AJMC
AJMC StaffAnniversarySeema Sonnad AwardStrategic Alliance Partners

Subscribe

  • News
  • Video
  • Podcasts
  • Journals
  • Conferences
  • Events
  • Resources
  • CE
  • About AJMC
  • Subscribe
  • Biosimilars
  • Cardiorenalmetabolic
    • Cardiomyopathy
    • Cardiovascular
    • Chronic Kidney Disease
    • Diabetes
    • Heart Failure
    • Type 1 Diabetes
  • Dermatology
    • Alopecia
    • Atopic Dermatitis
    • Chronic Hand Eczema
    • Psoriasis
  • Gastroenterology
  • Hematology
    • ALL/AML
    • CLL/SLL
    • GVHD
    • Hemophilia
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
    • Non-Hodgkin Lymphoma
    • Rare Blood
  • Hepatology
    • Hepatitis
    • Liver
    • MASH
  • Immunology
    • Allergy
    • Autoimmune
    • Inflammation
    • Lupus
    • Myasthenia Gravis
    • Rheumatoid Arthritis
  • Infectious Disease
    • COVID-19
    • HIV
    • RSV
    • Vaccines
  • Mental Health
    • Major Depressive Disorder
    • Sleep
  • Neurology
    • Duchenne Muscular Dystrophy
    • Epilepsy
    • Multiple Sclerosis
    • Parkinson Disease
  • Obesity
  • Oncology
    • Breast Cancer
    • Cholangiocarcinoma
    • Colorectal Cancer
    • Immuno-Oncology
    • Liver Cancer
    • Non–Small Cell Lung Cancer
    • Ovarian Cancer
    • Prostate Cancer
    • Skin Cancer
    • Small Cell Lung Cancer
    • Soft Tissue Sarcoma
  • Ophthalmology
  • Pulmonology
    • COPD
    • Pulmonary Arterial Hypertension
  • Rare Disease
    • Spinal Muscular Atrophy
  • Respiratory
    • Asthma
    • Pulmonary Fibrosis
  • Rheumatology
  • Urology
    • Overactive Bladder
  • Women's Health
    • Endometriosis
  • Biosimilars
  • Bispecifics Network
  • Center on Health Equity & Access
  • Digital Health
  • Dosing & Delivery Innovations
  • Formulary
  • Gene Therapy
  • Guidelines
  • Health Care Administration
    • Employers
    • Medicare
    • Reimbursement
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Population Health
  • Product Approvals and Launches
  • Technology
  • Value-Based Care
Spotlight -
Free In-Person Regional Events Focused on Oncology and Population Health
Advertisement

Diane E. Holland, PhD, RN

Advertisement

Articles by Diane E. Holland, PhD, RN

Higher 30-Day and 60-Day Readmissions Among Patients Who Refuse Post Acute Care Services

ByMaxim Topaz, PhD, MA, RN,Youjeong Kang, PhD, MPH, RN,Diane E. Holland, PhD, RN,Brenda Ohta, PhD, MSW,Kathy Rickard, MSN, RN,Kathryn H. Bowles, PhD, RN, FAAN, FACMI
June 19th 2015

Although patients who refuse post acute care services are relatively young, well educated, and healthy, they are twice as likely to have 30- and 60-day readmissions compared with acceptors of services.

Advertisement

Latest Updated Articles

  • Higher 30-Day and 60-Day Readmissions Among Patients Who Refuse Post Acute Care Services
    Higher 30-Day and 60-Day Readmissions Among Patients Who Refuse Post Acute Care Services

    June 19th 2015



Advertisement
Advertisement

Trending on AJMC

1

Special Report: The Oncology Care Model, 10 Years Later

2

Weight Loss Drugs Can Improve Outcomes in Patients With Heart Failure and Obesity: Sandra Chaparro, MD

3

FDA Approves Tocilizumab-bavi for CAR-T-Induced CRS, Pediatric COVID-19

4

Patients on GLP-1s Increasingly Carry Diagnoses for New Indications

5

Long-Term Extension Data Support Durable Benefit of Rilzabrutinib in Persistent, Chronic ITP: David Kuter, MD, DPhil

Brand Logo
  • About
  • Contact
  • Editorial Boards
  • Advertise
  • Do Not Sell My Information
  • Terms & Conditions
  • Privacy Policy

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2026 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text